- Home
- ALDX vs RVNC Comparison
ALDX vs RVNC Comparison
Compare ALDX & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- RVNC
- Stock Information
- Founded
- ALDX 2004
- RVNC 1999
- Country
- ALDX United States
- RVNC United States
- Employees
- ALDX N/A
- RVNC N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- RVNC Health Care
- Exchange
- ALDX Nasdaq
- RVNC Nasdaq
- Market Cap
- ALDX 319.4M
- RVNC 320.5M
- IPO Year
- ALDX 2014
- RVNC 2014
- Fundamental
- Price
- ALDX $5.02
- RVNC $3.08
- Analyst Decision
- ALDX Strong Buy
- RVNC Hold
- Analyst Count
- ALDX 2
- RVNC 9
- Target Price
- ALDX $10.00
- RVNC $7.78
- AVG Volume (30 Days)
- ALDX 380.6K
- RVNC 3.5M
- Earning Date
- ALDX 11-07-2024
- RVNC 11-07-2024
- Dividend Yield
- ALDX N/A
- RVNC N/A
- EPS Growth
- ALDX N/A
- RVNC N/A
- EPS
- ALDX N/A
- RVNC N/A
- Revenue
- ALDX N/A
- RVNC $256,945,000.00
- Revenue This Year
- ALDX N/A
- RVNC $11.28
- Revenue Next Year
- ALDX N/A
- RVNC $27.21
- P/E Ratio
- ALDX N/A
- RVNC N/A
- Revenue Growth
- ALDX N/A
- RVNC 25.82
- 52 Week Low
- ALDX $2.71
- RVNC $2.30
- 52 Week High
- ALDX $6.55
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- ALDX 50.69
- RVNC 33.50
- Support Level
- ALDX $4.67
- RVNC $3.06
- Resistance Level
- ALDX $5.45
- RVNC $3.09
- Average True Range (ATR)
- ALDX 0.33
- RVNC 0.03
- MACD
- ALDX -0.01
- RVNC 0.04
- Stochastic Oscillator
- ALDX 44.30
- RVNC 7.45
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.